Pheast is a clinical-stage immuno-oncology company advancing pharmaceutical and biological research for the treatment of cancer.
Our scientific work spans the research and development of novel cancer therapies that direct the innate immune system against hard-to-treat tumors. We pursue this research through our own programs and through collaborations with academic institutions, research laboratories, and clinical partners.
Discovery research into the biology of cancer and the innate immune system, including novel macrophage checkpoint targets.
Developing novel anti-cancer therapeutics, advancing candidate molecules from discovery through clinical evaluation.
Scientific research in the field of cancer and immuno-oncology, advancing next-generation innate immunotherapies.
Pheast partners with academic and research institutions to advance the science of cancer immunotherapy. These collaborations support the discovery and development of new treatments and reflect our commitment to working alongside leading scientists and clinical investigators.
